TriangleNCT01592370 · OUTCOME
Best Overall Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month
What was measured
the best response designation over the study as a whole, recorded between the date of first dose and the last efficacy assessment prior to subsequent therapy. Measured in Complete Response and Partial Response
Analysis population: All treated participants with available measurements (excluding Multiple Myeloma (MM) Group)
Groups in this outcome
Nivolumab Monotherapy (Expansion)
3mg/kg of nivolumab
Nivolumab + Ipilimumab
3 mg/kg of nivolumab and 1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W
Nivolumab + Lirilumab
3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W
| Group | Source count |
|---|---|
| Nivolumab Monotherapy (Expansion) | 77 |
| Nivolumab + Ipilimumab | 58 |
| Nivolumab + Lirilumab | 62 |
Reported measurements
Complete Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab Monotherapy (Expansion) | 10.4 | Not reported | 4.6 | 19.4 | Not reported |
| Nivolumab + Ipilimumab | 13.8 | Not reported | 6.1 | 25.4 | Not reported |
| Nivolumab + Lirilumab | 9.7 | Not reported | 3.6 | 19.9 | Not reported |
Partial Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab Monotherapy (Expansion) | 33.8 | Not reported | 23.4 | 45.4 | Not reported |
| Nivolumab + Ipilimumab | 34.5 | Not reported | 22.5 | 48.1 | Not reported |
| Nivolumab + Lirilumab | 29.0 | Not reported | 18.2 | 41.9 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.6
- upper Limit
- 19.4
- value
- 10.4
- group Id
- OG001
- lower Limit
- 6.1
- upper Limit
- 25.4
- value
- 13.8
- group Id
- OG002
- lower Limit
- 3.6
- upper Limit
- 19.9
- value
- 9.7
- title
- Complete Response
- categories
- measurements
- group Id
- OG000
- lower Limit
- 23.4
- upper Limit
- 45.4
- value
- 33.8
- group Id
- OG001
- lower Limit
- 22.5
- upper Limit
- 48.1
- value
- 34.5
- group Id
- OG002
- lower Limit
- 18.2
- upper Limit
- 41.9
- value
- 29.0
- title
- Partial Response
- denoms
- counts
- group Id
- OG000
- value
- 77
- group Id
- OG001
- value
- 58
- group Id
- OG002
- value
- 62
- units
- Participants
- description
- the best response designation over the study as a whole, recorded between the date of first dose and the last efficacy assessment prior to subsequent therapy. Measured in Complete Response and Partial Response
- dispersion Type
- 95% Confidence Interval
- groups
- description
- 3mg/kg of nivolumab
- id
- OG000
- title
- Nivolumab Monotherapy (Expansion)
- description
- 3 mg/kg of nivolumab and 1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W
- id
- OG001
- title
- Nivolumab + Ipilimumab
- description
- 3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W
- id
- OG002
- title
- Nivolumab + Lirilumab
- param Type
- NUMBER
- population Description
- All treated participants with available measurements (excluding Multiple Myeloma (MM) Group)
- reporting Status
- POSTED
- time Frame
- Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month
- title
- Best Overall Response
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice